Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy
- 23 April 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 323, 282-292
- https://doi.org/10.1016/j.jconrel.2020.04.028
Abstract
No abstract availableFunding Information
- PhRMA Foundation
- University of North Carolina at Chapel Hill (R01NS097507-02, F32CA225199)
This publication has 88 references indexed in Scilit:
- Evolutionary etiology of high-grade astrocytomasProceedings of the National Academy of Sciences of the United States of America, 2013
- Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgeryInternational Journal of Nanomedicine, 2013
- Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastomaRadiation Oncology, 2013
- Intracerebral delivery of Carboplatin in combination with either 6 MV Photons or monoenergetic synchrotron X-rays are equally efficacious for treatment of the F98 rat gliomaJournal of Experimental & Clinical Cancer Research, 2012
- Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery CarrierPolymers, 2011
- Acetalated dextran is a chemically and biologically tunable material for particulate immunotherapyProceedings of the National Academy of Sciences of the United States of America, 2009
- Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumoursBritish Journal of Cancer, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Acetal-Derivatized Dextran: An Acid-Responsive Biodegradable Material for Therapeutic ApplicationsJournal of the American Chemical Society, 2008
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient GlioblastomaPLoS Medicine, 2008